MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0087134
Market Cap
₹181 Cr
CORALAB · BSE
Share Price
₹498.00
-1.77% today
Revenue
₹85.90 Cr
FY 2025-26 · -25.3% YoY
EBITDA
₹15.21 Cr
Margin 17.7%
Net Profit
₹15.98 Cr
FY 2025-26 · -35.4% YoY
P/E (TTM)
9.9x
P/B 0.9x
ROE
8.0%
ROCE 11.1%
Debt / Equity
0.02
Interest cover 1.3x
About Coral Laboratories Limited
Data last updated:
Coral Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 February 1997 and has been in existence for over 29 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24231MH1997PLC422233. Its GSTIN is 27AAACC4421G2Z2 (Maharashtra). The company holds 9 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524506.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹3.57 Cr. It was formerly known as Coral Laboratories Private Limited. It is led by directors including Girish Madanlal Dhameja (Whole-Time Director) and Saurabh Kamlesh Shah.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹85.9 Cr, a decline of 25.3% compared to the previous year. For the same year it recorded a net profit of ₹15.98 Cr (net margin 18.6%) and EBITDA of ₹15.21 Cr (EBITDA margin 17.7%). The net worth stands at ₹209.11 Cr (up 3.9% YoY). Total assets are valued at ₹214.17 Cr (up 4.2% YoY).
The company has about 103 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Coral Laboratories. As per MCA filings, the company has open charges of ₹31.05 Cr and satisfied charges of ₹1.97 Cr on record.
Coral Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0087134). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website corallab.com.
Company details
CIN L24231MH1997PLC422233
Registration Number 422233
Incorporation Date 06 February 1997
ROC Mumbai
Listing Status Listed - Listed on BSE (524506)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0087134
CIN history
Coral Laboratories has one previous CIN (Corporate Identification Number): L24231GJ1997PLC031669. The current CIN is L24231MH1997PLC422233, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231MH1997PLC422233 | Current |
| L24231GJ1997PLC031669 | Previous |
Key People
Girish Madanlal Dhameja Whole-Time Director Saurabh Kamlesh Shah Director Sushma Shashi Kadkade Director Recognitions & Rankings of Coral Laboratories
Contact details
Coral Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is corallab.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressShed No. 3B Patanwala Compound, Opp Shreyas Lbs Marg Ghatkopar (West), Mumbai, Maharashtra, India – 400086
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Coral Laboratories Limited, buy the company report.
Comprehensive company report
Coral Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Coral Laboratories operates one associated brand: Coral Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of generic drugs | corallab.com |
Financials of Coral Laboratories Limited
FY 2025-26 filings availableCoral Laboratories Limited reported revenue of ₹85.9 Cr (down 25.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹85.90 Cr
-25.3% YoY
EBITDA
₹15.21 Cr
-40.3% YoY
Profit After Tax
₹15.98 Cr
-35.4% YoY
Net Worth
₹209 Cr
+3.9% YoY
Total Assets
₹214 Cr
+4.2% YoY
Total Debt
₹4.33 Cr
+21.6% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 85.90 | 115 | 83.66 | 78.12 | 75.61 | 96.57 | 70.58 |
| Revenue growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| EBITDA | 15.21 | 25.46 | 16.07 | 3.81 | 8.21 | 15.86 | 5.42 |
| EBITDA margin | +17.7% | +22.1% | +19.2% | +4.9% | +10.9% | +16.4% | +7.7% |
| Profit before tax | 23.11 | 32.46 | 20.72 | 8.22 | 11.85 | 17.63 | 9.11 |
| Net profit | 15.98 | 24.72 | 15.90 | 6.41 | 8.31 | 13.56 | 7.12 |
| Net profit margin | +18.6% | +21.5% | +19.0% | +8.2% | +11.0% | +14.0% | +10.1% |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Balance sheet | |||||||
| Total assets | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Net worth | 209 | 201 | 177 | 155 | 156 | 137 | 116 |
| Total debt | 4.33 | 3.56 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Cash & bank | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Net working capital | 125 | 128 | 103 | 87.81 | 89.56 | 88.23 | 76.67 |
| Cash flow | |||||||
| Cash from operations | 15.62 | (1.22) | (5.46) | 12.67 | 6.08 | 0.93 | (3.86) |
| Cash from investing | (17.71) | (0.15) | 1.40 | (2.61) | (6.05) | (0.07) | (1.55) |
| Cash from financing | 0.06 | 2.71 | 0.01 | (6.43) | 0.15 | 0.35 | 3.56 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.62 | 26.48 | 21.56 | 19.03 | 18.82 | 28.13 | 22.99 | 32.23 |
| Revenue growth (YoY) | +57.4% | -5.9% | -6.2% | -41.0% | -40.6% | - | - | - |
| Other income | 2.15 | 2.65 | 2.49 | 3.03 | 2.05 | 2.48 | 2.52 | 2.54 |
| Total expenses | 24.14 | 20.29 | 19.67 | 14.10 | 16.64 | 26.22 | 16.67 | 25.72 |
| EBITDA | 5.48 | 6.19 | 1.89 | 4.93 | 2.18 | 1.91 | 6.32 | 6.51 |
| EBITDA margin | +18.5% | +23.4% | +8.8% | +25.9% | +11.6% | +6.8% | +27.5% | +20.2% |
| Depreciation | 0.66 | 0.54 | 0.69 | 0.45 | 0.45 | 0.51 | 0.50 | 0.51 |
| Interest | 0.03 | 0.01 | 0.00 | 0.10 | 0.06 | 0.04 | 0.02 | 0.01 |
| Profit before tax | 6.94 | 8.29 | 3.69 | 7.41 | 3.72 | 3.84 | 8.32 | 8.53 |
| Tax | 1.56 | 3.06 | 0.92 | 1.60 | 1.16 | 1.02 | 2.17 | 2.15 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.62 | 26.48 | 21.56 | 19.03 | 18.82 | 28.13 | 22.99 | 32.23 |
| Revenue growth (YoY) | +57.4% | -5.9% | -6.2% | -41.0% | -40.6% | - | - | - |
| Other income | 2.15 | 2.65 | 2.49 | 3.03 | 2.05 | 2.48 | 2.52 | 2.54 |
| Total expenses | 24.14 | 20.29 | 19.67 | 14.10 | 16.64 | 26.22 | 16.67 | 25.72 |
| EBITDA | 5.48 | 6.19 | 1.89 | 4.93 | 2.18 | 1.91 | 6.32 | 6.51 |
| EBITDA margin | +18.5% | +23.4% | +8.8% | +25.9% | +11.6% | +6.8% | +27.5% | +20.2% |
| Depreciation | 0.66 | 0.54 | 0.69 | 0.45 | 0.45 | 0.51 | 0.50 | 0.51 |
| Interest | 0.03 | 0.01 | 0.00 | 0.10 | 0.06 | 0.04 | 0.02 | 0.01 |
| Profit before tax | 6.94 | 8.29 | 3.69 | 7.41 | 3.72 | 3.84 | 8.32 | 8.53 |
| Tax | 1.56 | 3.06 | 0.92 | 1.60 | 1.16 | 1.02 | 2.17 | 2.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.90 | 115 | 83.66 | 78.12 | 75.61 | 96.57 | 70.58 |
| Revenue growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| Other income | 10.21 | 9.11 | 6.63 | 6.93 | 5.77 | 3.79 | 5.89 |
| Total expenses | 70.69 | 89.55 | 67.59 | 74.31 | 67.40 | 80.71 | 65.16 |
| Employee cost | 15.92 | 14.74 | 11.20 | 11.13 | 11.23 | 10.18 | 9.70 |
| EBITDA | 15.21 | 25.46 | 16.07 | 3.81 | 8.21 | 15.86 | 5.42 |
| EBITDA margin | +17.7% | +22.1% | +19.2% | +4.9% | +10.9% | +16.4% | +7.7% |
| Depreciation | 2.14 | 2.01 | 1.98 | 2.18 | 1.99 | 1.98 | 2.01 |
| Interest | 0.17 | 0.10 | 0.00 | 0.34 | 0.14 | 0.04 | 0.19 |
| Profit before tax | 23.11 | 32.46 | 20.72 | 8.22 | 11.85 | 17.63 | 9.11 |
| Tax | 6.73 | 8.31 | 4.94 | 1.78 | 2.81 | 4.06 | 1.99 |
| Net profit | 15.98 | 24.72 | 15.90 | 6.41 | 8.31 | 13.56 | 7.12 |
| Net profit margin | +18.6% | +21.5% | +19.0% | +8.2% | +11.0% | +14.0% | +10.1% |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 |
| Reserves & surplus | 206 | 198 | 174 | 151 | 152 | 133 | 112 |
| Shareholders' funds (net worth) | 209 | 201 | 177 | 155 | 156 | 137 | 116 |
| Secured loans | 4.33 | 3.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Total debt | 4.33 | 3.56 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Total liabilities | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Assets | |||||||
| Gross block | 71.61 | 51.45 | 51.43 | 50.66 | 47.07 | 42.74 | 41.80 |
| Net block | 44.13 | 22.73 | 24.28 | 25.27 | 23.78 | 21.44 | 22.56 |
| Capital work in progress | 0.04 | 2.48 | 0.00 | 0.00 | 1.72 | 0.50 | 0.00 |
| Investments | 46.11 | 52.34 | 49.75 | 41.29 | 46.18 | 33.18 | 24.87 |
| Inventories | 20.53 | 9.87 | 15.16 | 12.50 | 18.36 | 21.67 | 19.30 |
| Sundry debtors | 29.43 | 33.64 | 28.19 | 23.42 | 38.11 | 39.16 | 34.41 |
| Cash & bank balances | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Loans & advances | 25.14 | 25.62 | 23.51 | 23.33 | 15.09 | 13.88 | 12.14 |
| Total current assets | 148 | 149 | 128 | 99.66 | 109 | 110 | 95.84 |
| Total current liabilities | 22.98 | 21.40 | 24.90 | 11.85 | 19.48 | 21.31 | 19.17 |
| Net working capital | 125 | 128 | 103 | 87.81 | 89.56 | 88.23 | 76.67 |
| Total assets | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.41 | 2.07 | 6.13 | 2.51 | 2.32 | 1.11 | 2.97 |
| Net cash from operating activities | 15.62 | (1.22) | (5.46) | 12.67 | 6.08 | 0.93 | (3.86) |
| Net cash from investing activities | (17.71) | (0.15) | 1.40 | (2.61) | (6.05) | (0.07) | (1.55) |
| Net cash from financing activities | 0.06 | 2.71 | 0.01 | (6.43) | 0.15 | 0.35 | 3.56 |
| Net change in cash | (2.03) | 1.33 | (4.06) | 3.62 | 0.18 | 1.21 | (1.86) |
| Closing cash | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| EBITDA growth | -40.3% | +58.4% | +321.8% | -53.6% | -48.2% | +192.6% | - |
| PBT growth | -28.8% | +56.7% | +152.1% | -30.6% | -32.8% | +93.5% | -41.3% |
| Net income growth | -35.4% | +55.5% | +148.1% | -22.9% | -38.7% | +90.5% | - |
| Revenue CAGR (3Y) | +3.2% | +15.0% | -4.7% | +3.4% | -6.0% | +1.5% | -9.6% |
| EBITDA CAGR (3Y) | +58.6% | +45.8% | +0.4% | -11.1% | -12.9% | +1.1% | -38.2% |
| Profitability & leverage | |||||||
| Net income margin | +19.1% | +21.0% | +18.9% | +8.2% | +12.0% | +14.1% | +10.1% |
| Return on capital employed | +11.1% | +17.0% | +12.3% | +5.2% | +7.7% | +13.3% | +7.8% |
| Return on net worth | +8.0% | +12.8% | +9.5% | +4.2% | +6.2% | +10.7% | +6.2% |
| Debt / equity | 0.02 | 0.01 | 0.00 | 0.02 | 0.04 | 0.05 | 0.03 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.30 | 0.43 | 0.00 | 20.86 | 2.25 | 0.29 | 5.57 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.40 | 2.24 | 1.64 | 1.60 | 1.68 | 2.28 | 1.71 |
| Inventory turnover | 5.65 | 9.19 | 6.05 | 5.06 | 3.78 | 4.71 | 3.98 |
| Debtors turnover | 2.72 | 3.72 | 3.24 | 2.54 | 1.96 | 2.63 | 2.18 |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Dividend per share (₹) | 2.00 | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 585.33 | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 | 323.77 |
To see the full year-wise statements and ratios of Coral Laboratories Limited, buy the company report.
Board of directors of Coral Laboratories Limited
Coral Laboratories has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Saurabh Kamlesh Shah | Director | 28 May 2019 | 7 Years 4 Months | Current |
| Girish Madanlal Dhameja | Whole-Time Director | 26 May 2017 | 9 Years 4 Months | Current |
| Sushma Shashi Kadkade | Director | 26 May 2017 | 9 Years 4 Months | Current |
| Rajendrasinh Ajitsinh Rana | Director | 03 Sep 2021 | 5 Years 1 Months | Current |
| Malay Sureshkumar Doshi | Director | 27 May 2021 | 5 Years 4 Months | Current |
| Pooja Sanjiv Hindia | Director | 09 Aug 2024 | 2 Years 2 Months | Current |
Peer comparison
Coral Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Lifecare Neuro Products Limited | ₹91.88 Cr (FY 2024) | 14.0% | Nalagarh, Himachal Pradesh, India | |||
| Sydler Remedies Private Limited | ₹91.31 Cr (FY 2025) | -30.0% | Aurangabad, Maharashtra, India | |||
| S. A. Pharmachem Private Limited | ₹91.25 Cr (FY 2025) | -54.0% | Mumbai, Maharashtra, India | |||
| Gorakh Nath Formulations Private Limited | ₹89.91 Cr (FY 2024) | -3.0% | Meerut, Uttar Pradesh, India | |||
| Agog Pharma Limited | ₹89.88 Cr (FY 2024) | -7.0% | Mumbai, Maharashtra, India | |||
| Alcedo Pharmachem Private Limited | ₹89.55 Cr (FY 2025) | 26.0% | Hyderabad, Telangana, India | |||
| Shrey Nutraceuticals and Herbals Private Limited | ₹89.53 Cr (FY 2025) | 263.0% | New Delhi, Delhi, India | |||
| Verdant Life Sciences Private Limited | ₹89.48 Cr (FY 2025) | 6.0% | Andhra Pradesh, India | |||
| Coral Laboratories Limitedthis company | ₹85.9 Cr (FY 2026) | ₹15.98 Cr | 18.6% | -25.3% | 103 | Mumbai, Maharashtra, India |
To see the full peer comparison of Coral Laboratories Limited, buy the company report.
Auditor
Coral Laboratories Limited is audited by M. A. Parekh & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M. A. Parekh & Associates | FY 2024 | 121973W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 71.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 28.50%.
Mar 2026
QUARTER
71.50% Promoters
28.50% Retail & Others
Promoter holding - history
Now 71.50% · Mar 2026High 71.50% · Jun 2025Low 71.50% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 71.50% | 71.50% | 71.50% | 71.50% |
| Public | 28.50% | 28.50% | 28.50% | 28.50% |
Charges & borrowings
Open charges
₹31.05 Cr
Satisfied charges
₹1.97 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Jan 2019 | 100240261 | Hdfc Bank Limited | ₹23.35 Cr | Open | |
| 28 Dec 2006 | 10036279 | Hdfc Bank Limited | ₹7.7 Cr | Open | |
| 13 Jul 2000 | 80026913 | Bank of Baroda | ₹1.97 Cr | Satisfied |
To see the full charge records of Coral Laboratories Limited, buy the company report.
Total charge records: 3 View all charges
Legal cases
No court or tribunal cases involving Coral Laboratories Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Coral Laboratories Limited has 19 MSME Form 1 returns on record between 2019 and 2024, listing 6,363 overdue payments to 149 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 149)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| QCS Labs LLP | |||
| an individual supplier | |||
| R G Technologies | |||
| an individual supplier | |||
| Saroj Art Printers Private Limited |
To see the full MSME payment records of Coral Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Coral Laboratories Limited has a workforce of 103 employees on its EPFO records as of Mar 29, 2025, across 2 active EPFO establishments.
Employee count
103
Active EPFO establishments
2
Employee growth
13.19%
GST
Coral Laboratories has 9 GST registrations: 2 active and 7 cancelled or inactive.
Total GSTINs
9
Active
2
Cancelled / inactive
7
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACC4421G2Z2 | Maharashtra | Active | 07 Mar 2025 |
| 05AAACC4421G1Z9 | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Coral Laboratories Limited, buy the company report.
Recent activity
Coral Laboratories Limited has 30 board changes on record since 2000: 18 appointments and 12 cessations. The latest: Sheela Rupesh Kamdar ceased to be Director on 11 Aug 2024.
Filing
Coral Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Coral Laboratories Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Ceased
Sheela Rupesh Kamdar ceased to be Director.
Appointed
Pooja Sanjiv Hindia was appointed as Director.
Ceased
Ruchi Vikash Pipara ceased to be Company Secretary.
Appointed
Ruchi Vikash Pipara was appointed as Company Secretary.
Charges
A charge with Hdfc Bank Limited of Rs. 23.35 Cr registered on 17 Jan 2019 with Charge ID 100240261 was modified on 17 Feb 2023.
Ceased
Sanket Sharad Mehta ceased to be Director.
Ceased
Purvi Chetan Doshi ceased to be Director.
Appointed
Rajendrasinh Ajitsinh Rana was appointed as Director.
Appointed
Malay Sureshkumar Doshi was appointed as Director.
Appointed
Purvi Chetan Doshi was appointed as Director.
28 earlier events are in the company report.
Frequently asked questions
Coral Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 February 1997 (29+ years old) and is registered under CIN L24231MH1997PLC422233. Listed on BSE: 524506.
Coral Laboratories reported revenue of ₹85.9 Cr for FY 2025-26 (down 25.3% YoY) based on standalone financials.
Coral Laboratories has 6 current directors:
- Girish Madanlal Dhameja - Whole-Time Director
- Saurabh Kamlesh Shah - Director
- Sushma Shashi Kadkade - Director
- Rajendrasinh Ajitsinh Rana - Director
- Malay Sureshkumar Doshi - Director
- Pooja Sanjiv Hindia - Director
The latest financial statements of Coral Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Coral Laboratories is 27AAACC4421G2Z2, registered in Maharashtra. The company has 9 GST registrations in all, of which 2 are active and 7 are cancelled or inactive. Other active GSTINs include 05AAACC4421G1Z9 (Uttarakhand).
The CIN (Corporate Identification Number) of Coral Laboratories is L24231MH1997PLC422233. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Coral Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 524506).
Coral Laboratories was incorporated on 06 February 1997, making it 29+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Coral Laboratories by revenue are Lifecare Neuro Products Limited, Sydler Remedies Private Limited, S. A. Pharmachem Private Limited, Gorakh Nath Formulations Private Limited, Agog Pharma Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sheela Rupesh Kamdar ceased to be Director on 11 Aug 2024. Pooja Sanjiv Hindia was appointed as Director on 09 Aug 2024. Ruchi Vikash Pipara ceased to be Company Secretary on 13 Jul 2024. Coral Laboratories has 30 board changes on record in total.
Yes, Coral Laboratories is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0087134).
Coral Laboratories has 19 MSME Form 1 returns on record between 2019 and 2024, listing 6,363 overdue payments to 149 micro and small suppliers. The latest return was filed on 01 May 2024.